Dhruv Varshney

Dhruv Varshney is an accomplished scientist specializing in bioengineering and immuno-oncology, currently serving as Associate Scientist III at Ensoma since April 2022. Varshney has made significant contributions to in vivo gene therapy studies aimed at demonstrating safety, efficacy, and pharmacokinetics for IND/CTA submissions. Previously, Varshney held roles at the MIT Koch Institute, where innovations included a self-boosting microparticle and automated microneedle printer for therapeutic delivery, and at Rice University, developing scalable drug delivery technologies. Early experience included research at The University of Tulsa, focusing on alternative synthetic processes, and other roles involving quality control and data analysis. Varshney holds a Master of Bioengineering from Rice University and dual Bachelor's degrees in Biochemistry and Mathematics from The University of Tulsa.